OPEN MINDS, The Behavioral Health & Social Service Industry Analyst Industry News Eli Lilly and Company stock tumbled 31% from just over $107 to $75 per share following a decision by the Court of Appeals for the Federal Circuit in Washington, District of Columbia, on August 9, 2000, regarding Lilly's patent for Prozac. The court reversed a decision in the case of Eli Lilly and Company v. Barr Laboratories, et al that had given Lilly's antidepressant drug Prozac patent protection through December 2003, raising the likelihood for generic competition as early as February 2001. On March 8, 2000 . . .

OPEN MINDS, The Behavioral Health & Social Service Industry Analyst Industry News Eli Lilly and Company stock tumbled 31% from just over $107 to $75 per share following a decision by the Court of Appeals for the Federal Circuit in Washington, District of Columbia, on August 9, 2000, regarding Lilly's patent for Prozac. The court reversed a decision in the case of Eli Lilly and Company v. Barr Laboratories, et al that had given Lilly's antidepressant drug Prozac patent protection through December 2003, raising the likelihood for generic competition as early as February 2001. On March 8, 2000 . . .